BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

Indapta is sidestepping genome engineering for its universal NK cells, a strategy that not only reduces manufacturing costs but also broadens the number of cancer patients it could treat relative to genetically edited allogeneic NK...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

Innate Pharma's trifunctional NK cell engagers for multiple cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; lymphoma; solid tumors Innate Pharma S.A. showed that its trifunctional NK cell engager platform could be deployed against lymphoma, lung cancer and solid tumors. The trifunctional NK cell engagers...
BC Extra | Jul 3, 2019
Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
BC Extra | Apr 16, 2018
Preclinical News

Fate's CAR Ts show efficacy

Fate Therapeutics Inc. (NASDAQ:FATE) presented data Monday at the American Association for Cancer Research meeting in Chicago showing that its off-the-shelf CAR T cell therapy FT819 elicited an immune response in cell studies. FT819 cells...
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BC Extra | Aug 11, 2017
Preclinical News

Study links FNAIT miscarriages to NK cells

In a paper published in Nature Communications , a team including scientists from St. Michael's Hospital and University of Toronto showed that NK cell activation leads to placental dysfunction and miscarriages in fetal/neonatal alloimmune thrombocytopenia (FNAIT)....
BC Innovations | May 23, 2017
Distillery Therapeutics


INDICATION: Cancer Mouse studies suggest inhibiting FCGR2B and FCGR3 on macrophages could enhance effects of anti- PD-1 antibodies on tumors. In a xenograft mouse model of colorectal cancer treated with an anti-PD-1 antibody, intravital microscopy...
BioCentury | Apr 7, 2017

Combo quest

By leading Viracta Therapeutics Inc. ’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal. Wicklow...
BioCentury | Mar 17, 2017
Emerging Company Profile

B-ing persistent

Aleta Biotherapeutics Inc. is extending the use of CD19 -targeting CAR T cells by coating non-B cell tumors with the antigen. President and CSO Paul Rennert told BioCentury the key to effective CAR T cell...
BioCentury | Aug 3, 2015

NK-ocking out cancer

Patrick Soon-Shiong is building what he hopes will be a suite of companies under the NantWorks LLC umbrella that together will help revolutionize cancer treatment. The latest is cancer immunotherapy company NantKwest Inc. (NASDAQ:NK), which...
Items per page:
1 - 10 of 14